H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

Group Dinner Meeting to be held in New York on February 5 at 6 pm hosted by Truist. Maximize Your Portfolio with Data Driven Insights:Leverage ...

CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10. The firm has a 50-day moving average price of $43.76 and a 200 day moving average price of $47.16.

Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucom ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

How much is Crispr Therapeutics Ag stock worth? Invest with precise valuations. Get Report.

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

Welcome to the September edition of Changing Faces. September ushered in a wave of significant appointments across the pharmaceutical and biotechnology industries, with companies from big pharma ...

Option Chain is currently not available. Nasdaq provides call and put options information of stocks. Financial analysts and individual investors can rely on the chain to gauge the stock's ...